Aptinyx Inc. (APTX) News
Filter APTX News Items
APTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest APTX News From Around the Web
Below are the latest news stories about APTINYX INC that investors may wish to consider to help them evaluate APTX as an investment opportunity.
Horizon (HZNP) Q1 Earnings and Revenues Miss EstimatesHorizon Therapeutics (HZNP) reports lower-than-expected first-quarter 2023 results as it misses the Zacks Consensus Estimates for both revenues and earnings. |
Anixa (ANIX) Falls 25% Despite Positive Breast Cancer Study DataAnixa Biosciences (ANIX) announces positive top-line data from its phase Ia study evaluating the safety of its breast cancer vaccine. However, the stock plunges 25% in the absence of efficacy reports. |
Agenus (AGEN) Rises on Fast Track Tag for Cancer Combo DrugThe FDA grants Fast Track Designation to Agenus' (AGEN) phase II study evaluating the botensilimab/balstilimab combination in non-MSI-H colorectal cancer patients. The stock jumps 16% following the news. |
Adaptimmune (ADAP) Up 7%, Gets T-Cell Programs Rights From GSKAdaptimmune Therapeutics (ADAP) enters into a transition deal with GSK to regain rights to its proprietary T-cell therapy programs. Shares of the company surges 7% following the news. |
Merck (MRK) Keytruda Studies in Difficult-to-Treat Cancers FailMerck (MRK) and Eisai announce the discontinuation of the phase III LEAP-003 study seeking approval of the Keytruda and Lenvima combo. Another phase III LEAP-017 study fails to meet goals. |
Seagen's (SGEN) Padcev & Keytruda Combo Gets FDA Accelerated NodThe FDA grants accelerated approval to Seagen (SGEN) and partner, Astellas' combination therapy of Padcev with Merck's Keytruda for the treatment of first and second-line metastatic urothelial cancer. |
Aptinyx Reports on Fourth Quarter and Full Year 2022 Results and Highlights and Review of Strategic AlternativesEVANSTON, Ill., March 30, 2023--Aptinyx Inc. (Nasdaq: APTX) today reported recent business updates and financial results for the fourth quarter and full year 2022. |
Here's Why Aptinyx Inc. (APTX) Is a Great 'Buy the Bottom' Stock NowAfter losing some value lately, a hammer chart pattern has been formed for Aptinyx Inc. (APTX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term. |
Bicycle (BCYC) up on Collaboration With Novartis for ConjugatesBicycle (BCYC) and Novartis enter into a collaboration agreement to develop, manufacture and commercialize conjugate drugs for several oncology indications. Stock soars following the news. |
Vertex (VRTX) Inks Licensing Deal With CRISPR for Diabetes DrugVertex Therapeutics (VRTX) enters into a licensing agreement with CRISPR for the latter's gene-editing technology to accelerate the development of its type I diabetes hypoimmune therapy programs. |